Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Attenuated Mopeia/Lassa Reassortant 29 (ML29), a Vaccine Candidate

Juan Carlos Zapata1*, Ricardo Carrion, Jr.2, Jean L. Patterson2, Oswald Crasta3, Yan Zhang3, Sachin Mani4, Marti Jett4, Bhawna Poonia1, Mahmoud Djavani1, David M. White5, Igor S. Lukashevich1*a, Maria S. Salvato1

1 Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 2Texas Biomedical Research Institute, San Antonio, Texas, United States of America, 3Virginia Bioinformatics Institute at Virginia Tech, Blacksburg, Virginia, United States of America, 4Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America, 5Center for Disease Control and Prevention, Atlanta, Georgia, United States of America

Abstract

Lassa virus (LASV) is the causative agent of Lassa Fever and is responsible for several hundred thousand infections and thousands of deaths annually in West Africa. LASV and the non-pathogenic Mopeia virus (MOPV) are both rodent-borne African arenaviruses. A live attenuated reassortant of MOPV and LASV, designated ML29, protects rodents and primates from LASV challenge and appears to be more attenuated than MOPV. To gain better insight into LASV-induced pathology and mechanism of attenuation we performed gene expression profiling in human peripheral blood mononuclear cells (PBMC) exposed to LASV and the vaccine candidate ML29. PBMC from healthy human subjects were exposed to either LASV or ML29. Although most PBMC are non-permissive for virus replication, they remain susceptible to signal transduction by virus particles. Total RNA was extracted and global gene expression was evaluated during the first 24 hours using high-density microarrays. Results were validated using RT-PCR, flow cytometry and ELISA. LASV and ML29 elicited differential expression of interferon-stimulated genes (ISG), as well as genes involved in apoptosis, NF-kB signaling and the coagulation pathways. These genes could eventually serve as biomarkers to predict disease outcomes. The remarkable differential expression of thrombomodulin, a key regulator of inflammation and coagulation, suggests its involvement with vascular abnormalities and mortality in Lassa fever disease.

Introduction

Lassa Fever (LF) is one of the most neglected tropical diseases and has the second highest global incidence of any viral hemorrhagic fever (VHF), after Dengue HF. The estimated “at risk” population in Sierra Leone, Guinea, and Nigeria, may be as high as 50 million. The number of symptomatic cases per year is around 300,000 with between 5,000 and 10,000 deaths [1] [2] [3]. LF is also one of the most prominent imported VHF affecting public health of non-endemic countries worldwide and has been classified as a category A bio-threat agent [4], [5], [2], [6].

Lassa virus (LASV) belongs to the *Arenaviridae*, a fast-growing family of rodent-borne viruses, currently including 22 enveloped viruses with bi-segmented, ambisense single-stranded RNA genomes divided into two groups [7], [8]. The Old World (OW) group contains the prototypic lymphocytic choriomeningitis virus (LCMV) which can cause neuropathology in adults, fetal abnormalities in newborns, and a fatal LF-like disease in immunocompromised patients. OW viruses also include LASV; and non-pathogenic viruses, Mopeia (MOPV), Mobala (MOBV), and Ippy (IPPYV), as well as newly-found LaJo pathogenic [9] and Luna (unknown pathogenicity) [10] viruses. The New World group includes Junin, Machupo, Guanarito, Sabia, and Chapare viruses associated with severe VHF in South America [11].

The disease mechanism for LF is still not clearly understood. As with other VHF, events that determine LF fatal outcome occur very early in the disease and depend on the host immune system [12], [13]. Macrophages (MP) and dendritic cells (DC) are the initial targets of infection, followed by viremic seeding of a wide variety of cells and organs. High viremia and elevated levels of...
Author Summary

The virulent Lassa fever virus (LASV) and the non-pathogenic Mopeia virus (MOPV) infect rodents and, incidentally, people in West Africa. The mechanism of LASV damage in human beings is unclear. There is no licensed Lassa fever vaccine and therapeutic intervention is usually too late. The ML29 vaccine candidate derived from Lassa and Mopeia viruses protects rodents and primates from Lassa fever disease. Peripheral blood mononuclear cells from healthy human subjects were exposed to either LASV or ML29 in order to identify early cellular responses that could be attributed to the difference in virulence between the two viruses. Differential expression of interferon-stimulated genes as well as coagulation-related genes could lead to an explanation for Lassa fever pathogenesis and indicate protective treatments for Lassa fever disease.

Materials and Methods

Viruses and cells

LASV (strain Josiah) was obtained from CDC (Atlanta, GA) and ML29 was previously described [25], [26], [27].

Vero E6 cells (ATCC, CRL-1586) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO-BRL) supplemented with 10% fetal bovine serum (FBS, GIBCO-BRL), 1% penicillin-streptomycin, and L-glutamine (2 mM). incubated at 37°C in 5% CO₂ for 24 hours. Vero cell monolayers were infected with LASV and ML29 at a multiplicity of infection (MOI) of 0.01 and incubated 1 hour at 37°C in 5% CO₂, washed with PBS and then covered in DMEM 2% FBS. Supernatants were collected at 48 and 72 hours post infection, titrated in Vero cells and stored at −70°C at 10⁷ PFU/ml.

Human PBMC were obtained by apheresis from healthy volunteers followed by Ficoll-hypaque isolation [37] and resuspended in RPMI 1640 medium with 10% heat-inactivated human AB serum (Sigma).

Monocytes were isolated from purified PBMC by plastic adherence and immature dendritic cells (DC) were generated from them after 5 days culture in supplemented RPMI. Briefly, the method for generating DC was to plate human PBMC at 1.67 x 10⁷ cells/2 ml/well in a 6-well plate in RPMI, 10% fetal calf serum. After 2 hrs, non-adherent cells were removed and the adherent monocytes were fed with 2.5 ml RPMI containing 20 ng/ml GM-CSF (Peprotech, Rocky Hill NJ), and 20 ng/ml IL-4 (Peprotech). After 5 days of incubation, cells were harvested, analyzed by flow cytometry, and processed for incubation with virus. On average, 22% of the cells were differentiated, monocyte-derived DC (DR+, CD11c+). [38].

Ethics statement

Human blood samples were used under an IRB exemption to Dr. Salvato for the use of de-identified human cells obtained through the Red Cross.

Human PBMC and DC exposure

1.2 x 10⁷ PBMC from healthy donors were exposed to 1 MOI of LASV or ML29 (BSL-4 facilities at SFRB, San Antonio, TX) for 45 minutes at 37°C in 5% CO₂ and plated in 6 well plates in duplicate. Supernatants and cells were harvested at 4, 8, and 24 hours post-exposure. Cells were re-suspended in Trizol and kept at −70°C for RNA isolation.

1 x 10⁷ DC from 3 healthy donors were exposed to 1 MOI of LASV, ML29 or LPS (as an inhibitor control: LPS is usually a positive control, here it was used to inhibit thrombomodulin) for 45 minutes at 37°C in 5% CO₂ (BSL-4 facilities at CDC, Atlanta, GA). Supernatants and cells were harvested at 24 hours post-exposure. Supernatants were kept at −70°C for ELISA analysis.

Gene expression profiling using cDNA microarrays

Total RNA was isolated from PBMC samples using the Trizol method (Invitrogen, Carlsbad, CA) followed by a cleaning step with Rneasy mini kit (Qiagen, Valencia, CA), according to the manufacturer’s instructions. Quality and quantity of all RNA samples were evaluated on the Agilent 2100 BioAnalyzer 116 system (Agilent Technologies, Palo Alto, CA) by looking at 18 & 28 s rRNA peaks and by the RIN (RNA integrity number). High quality RNA was labeled and hybridized according to Affymetrix protocols using the GeneChip human genome U133 Plus 2.0 array (Affymetrix, Santa Clara, CA) and as described previously [24]. This chip covers the whole human genome using 54,000 probe sets representing approximately 22,000 genes.
Microarray data analysis

Images from each hybridization were inspected manually and percentage of present calls of each array was checked. Cluster [39] and Principal Component Analyses (PCA) [40] against all conditions using genes with normalized maximum value/minimum value >5 were also performed. Raw data from the arrays were normalized at probe level using a robust multichip average of G+C content algorithm (gcRMA) [41], [42] and then log2 transformed. The detection calls (Present, Marginal, Absent) for each probe set were obtained using Affymetrix GeneChip Operating Software (GCOS) (http://www.affymetrix.com/browse/products.jsp?productId=131429&navMode=34000&navAction=jump&xlId=productsNav#1_1). Only genes with at least one present call across all compared hybridizations were selected for further statistical analysis. All data have been submitted under series record GSE41300.

For the identification of differentially-expressed genes the Linear Models for Microarray Data (LIMMA) package was used [43]. Due to high variation among donors the pairwise comparison Significance Analysis of Microarrays (SAM) was used to eliminate disturbance. PBMC from each donor were compared before and after exposure at different time points.

To identify the over-represented Gene Ontology (GO) terms in each list of differentially expressed genes from 3 donors and 2 repetitions, the GO:TermFinder was used [44]. GO terms with adjusted p value (false discovery rate or FDR) less than 0.05 were selected.

In order to identify over-represented Pathways from each list of differentially expressed genes from 3 donors and 2 repetitions, the Kegg’s pathway (with adjusted p value (FDR) less than 0.05 for each list of genes) was used.

Validation of cDNA array data by quantitative RT-PCR

Due to the high number of interferon-related genes involved in the LASV and ML29 gene profiles, they were selected for validation by RT-PCR. 24 hour post-exposure (hpe) RNA samples, from 3 donors, and 3 time points used in the microarray test, were evaluated by the Interferon and Receptor PCR Array Kit (Human Interferon and Receptor array, Cat# No. PAHS-064, SABiosciences, Frederick, MD). This platform tested 84 interferon-related genes and 5 housekeeping genes for data normalization. Briefly, 1 μg of RNA from PBMC was reverse-transcribed in a 20-μL reaction volume into first-strand cDNA using SuperArray’s ReactionReady First Strand cDNA Synthesis Kit (Cat. No C-01, SABiosciences) containing random and oligo d(T) primers. After mixing the cDNA with RT2 SYBR Green/ROX qPCR Master Mix (Cat. No PA-012, SABiosciences), 10 μL of the cDNA mixture was dispensed into a 96 well format plate RT² profiler PCR array (Cat. No. PAHS-064, SABiosciences).

Real-time PCR was performed on an ABI Fast 7900 Real-Time PCR System (Applied Biosystems, Foster City, CA) using the following cycling parameters: 10 min at 95°C (heat activation step); 40 cycles of 15 sec at 95°C, 1 min at 60°C. Relative changes in gene expression were calculated using the ΔΔCt (threshold cycle) method. This method first subtracts the ct (threshold cycle number) of the gene-average ct of the 5 housekeeping genes on the array to normalize to the RNA amounts. Finally the ΔΔCt is calculated which involves subtracting the normalized average ct of LASV samples -normalized average ct of the Control Samples. Then this ΔΔCt is raised to the negative power of 2 in order to calculate the fold changes. The p value was calculated using a 2-tailed Student’s t test. These results were treated to SAM data analysis to avoid donor variation.

Flow cytometry and ELISA analysis of thrombomodulin expression

Whole blood from healthy donors was collected in heparin tubes, mixed with 20 ng/ml lipopolysaccharide (LPS Cat No-dl3-ekpl, InvivoGen, San Diego, CA) as down-regulation control for thrombomodulin [45], MEM as non-stimulated control and ML29 virus. Then this mix was brought to 3 ml with RPMI 10% FBS and incubated for 4, 8, or 24 hours. For each time-point cells were stained with phycoerythrin-conjugated mouse anti-human thrombomodulin monoclonal antibody (PE-CD141, BD Biosciences, San Jose, CA) and fluorescein isothiocyanate mouse anti-human CD14+ antibody (FTTC-CD14+ BD Biosciences, San Jose, CA). Cells were collected (10,000 events per sample) using a FACSCalibur cytometer (BD Biosciences) and the data were analyzed using FlowJo 8.8.4 software (Tree Star, San Carlos, CA). The monocyte population was gated and percentages of double positive cells (CD14+ and CD141+) were determined.

Dendritic cells were isolated from 3 different individuals for virus exposure and expression of soluble thrombomodulin. Immature DC were derived from human PBMC as described above in “Viruses and cells”.

Soluble thrombomodulin was quantified by ELISA (Human Thrombomodulin ELISA kit. Cat. No ab46509, Abcam, Cambridge, MA), in DC supernatants after 24 hour of exposure to LPS, ML29, LASV or LASV plus LPS. Plates were read at 450 nm using SpectraMax M2 ELISA reader (Molecular Devices Corporation, Sunnyvale, CA). The estimated amount of thrombomodulin was calculated using the Softmax pro 4.8 program (Molecular Devices Corporation, Sunnyvale, CA) and presented in picograms per ml.

Results

Exposure of human PBMC to LASV and ML29 results in different transcription profiles

In a previous transcriptome profiling study using a surrogate LF model in monkeys we showed that significant changes in PBMC gene expression occurred during pre-viremic days 1, 2, and 3 [24], clearly differentiating pathogenic versus non-pathogenic infections even before detectable virus replication. Clearly, a large part of the response to viruses is due to signal transduction of uninfected bystander cells.

In this study, PBMC from three healthy donors were exposed to LASV or ML29 viruses at 1 MOI in duplicate and were collected at 4, 8, and 24 hours post-exposure (hpe) for isolation of total RNA. cDNA was hybridized to Affymetrix chips covering the whole human genome. Cluster and Principal Component Analysis (PCA) showed that all samples clustered together by time (4, 8, and 24 hpe), by donor (3 healthy donors) and by treatment (unexposed, LASV-exposed, and ML29-exposed cells) (Figure S1). Since donor variation exceeded treatment variation, pairwise Significance Analysis of Microarrays (SAM) was used to compare RNA samples before and after exposure for each donor at different time points. Differentially-expressed genes were defined as those that had at least a >2-fold changes with respect to media controls. A total of 122 genes were identified as being differentially expressed at tested time-points (Figure 1 and Table S1). Gene expression changes in ML29 and LASV-exposed PBMC were detected at 4 and 8 hpe respectively, with all genes up-regulated in LASV in contrast to ML29 with 11 down-regulated genes (4 at 4 hpe and 7 at 8 hpe). At 24 hpe LASV-treated PBMC showed the maximum changes (122 genes) in comparison with ML29-exposed samples.
Gene ontology analysis of global changes in LASV versus ML29-exposed PBMC

In order to have a general view of the pathways affected by both virus exposures, we performed gene ontology (GO) analysis of differentially expressed genes. The analyses revealed that the most affected genes were involved in type I IFN-stimulated pathways (21%–17 genes from 122), apoptosis (12.29%–15/122), and NF-kappa B pathways (10.65%–13/122) (Figure 2A). Although, several genes could be put into more than one category, the interferon-related genes had the higher percentage of presence. From those categories the immune response, defense response, and response to viruses were selected for validation analysis (Table 1). The most differentially expressed genes between LASV and ML29 are shown in Table 2.

LASV exposure up-regulates genes involved in innate immunity: IFN-stimulated genes, transcription factors, and genes involved in apoptosis

As shown in Figure 2A, the most striking differences involved gene expression in three different functional categories: IFN-stimulated, apoptosis, and NF-kB pathways, during the late time-point, 24 h after exposure.

To confirm the observed gene expression changes in PBMC exposed to LASV and ML29 viruses, the most affected probesets, the ISGs, were selected for further validation. RNA samples from the 24-hr LASV- and ML29-exposed cells were assayed in duplicate using a human IFN and Receptors qRT-PCR Super-array kit (see Methods). Levels of expression of 17 gene-targets were expressed in fold changes (Table 1 and figure 2B).

Exposure of human PBMC to LASV resulted in over-expression of all 17 IFN-stimulated genes by 2- to 100-fold over background. Exposure of PBMC to ML29 had relatively little effect on the 17 tested genes. Comparative analyses showed a good correlation (76%) between the two techniques, DNA array and IFN qRT-PCR array (Table 1). For a few genes measured in the DNA array, ML29 exposure gave a higher background than quantitation by real-time PCR. This is because the housekeeping genes we used for normalizing the PCR data, including GAPDH, were not constantly expressed in the compared data sets, whereas probesets used for normalizing the microarray data varied less than 0.04% in all data sets (see Methods).

The most affected gene, IFI6, is the first IFN-stimulated gene known to inhibit apoptosis [46]. Among other most affected genes were IFI35, IFITM1, IRF-7, and SP110. While the function of the IFI35 gene is not well-defined, the IFITM proteins have roles in immune cell signaling and adhesion, cancer, germ cell physiology, and bone mineralization. IFITMs are also viral restriction factors that block entry of Influenza, Ebola, Dengue and West Nile viruses but not arenavirus-envelope pseudotyped particles [47] [48] [49]. IRF-7 is over-expressed in LASV-exposed PBMC and others found that it could be up-regulated in 5-day LASV-infected monocyte-derived macrophages [50]. IRF-7 is also known to limit the burst size of LCMV in culture but is
not ultimately essential for LCMV clearance in vivo [51]. IRF-7 and IRF-3 are transcription factors which together with NF-kB and ATF-2/cJUN induce production of IFN-I. IRF-3 is required for the activation of IFN-β, which in turn, primes the expression of most IFN-α genes by IFN-induced IRF-7 through the STAT-1 pathway. Human SP110 plays an important role in resistance to intracellular pathogens such as human mycobacteria and intracellular cancers. Recently cellular proteins have been described that mediate the interaction of SP110 and viral proteins during viral infections [52].

Table 1. Validation of expression patterns of selected genes by quantitative RT-PCR.

| GenBank accession no. | Gene symbol | Fold changes in gene expression DNA microarray | Fold changes in gene expression qRT-PCR |
|-----------------------|-------------|-----------------------------------------------|----------------------------------------|
| NM_005101             | ISG15       | 28.95/14.82                                  | 17.58/14.82                             |
| NM_002038             | IFI6        | 44.70/5.99                                   | 10.41/3.08                             |
| NM_005333             | IFI35       | 16.78/6.38                                   | 9.75/1.76                              |
| NM_006417             | IFI44       | 29.96/18.52                                   | 11.64/2.19                             |
| NM_006820             | IFI44L      | 172.96/81.41                                 | 35.64/2.72                             |
| NM_022168             | IFIH1       | 4.66/4.68                                     | 3.45/1.60                              |
| NM_001548             | IFIT1       | 146.9/140.1                                  | 45.58/3.24                             |
| NM_001547             | IFIT2       | 25.60/27.30                                   | 5.35/2.42                              |
| NM_001549             | IFIT3       | 43.09/27.81                                  | 19.86/2.86                             |
| NM_003641             | IFITM1      | 6.48/4.84                                     | 4.6/1.50                               |
| NM_001572             | IRF7        | 7.51/2.92                                    | 5.81/1.75                              |
| NM_002462             | MX1         | 34.45/17.98                                  | 16.80/2.73                             |
| NM_002534             | OAS1        | 28.90/39.28                                   | 12.39/1.56                             |
| NM_004509             | SP110       | 6.33/2.48                                    | 2.99/1.43                              |
| NM_000575             | IL1A        | 23.57/1.28                                   | 2.33/1.31                              |
| NM_003810             | TNFS10      | 6.18/5.33                                     | 3.38/2.21                              |
| NM_007315             | STAT1       | 7.98/5.82                                     | 4.14/1.36                              |

There was 76% correlation between microarray and qRT-PCR.
*Two different readings for a particular gene in the same chip.

doi:10.1371/journal.pntd.0002406.g002
Among apoptosis-related genes, the most striking difference was observed in the expression of matrix metalloproteinase, MMP-1 (interstitial collagenase), up-regulated 65-fold in LASV-exposed cells versus ML-29-exposed cells (Table 2). Proteins of the MMP family normally breakdown extracellular matrix during embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. MMP-1 is known to interact with Tat, the HIV transactivating protein, and this interaction results in the degradation of Tat and depression of Tat-mediated neurotoxicity and transactivation [53].

Two other apoptosis-related genes, SPP1 and INHBA, were up-regulated 14- and 20-fold, respectively (Table 2). SPP1, a secreted arginine-glycine-aspartate (RGD)-containing phosphoprotein 1 (previous names: osteopontin, bone sialoprotein I), enhances IFN-γ and IL-12 production and contributes to host defense, bone formation, and wound healing by stimulating macrophage migration as well as protecting against viral and bacterial infections through its pro-Th1 effect [54]. Inhibin-beta A (INHBA) joins Inhibin-alpha to form a pituitary follicle-stimulating hormone (FSH) secretion inhibitor. Inhibin has been shown to negatively-regulate gonadal stromal cell proliferation and to have tumor-suppressor activity. INHBA is also up-regulated by vaccinia and inhibits a diverse array of cytokines by enabling vaccinia virus E3 protein to antagonize several distinct but interlinked signaling cascades [55].

Exposure of human PBMC to LASV was associated with strong up-regulation (22-25-fold) of CXCL6 and IL1A genes in comparison to ML29 exposure (Table 2). Among CXC chemokines, CXCL6, a granulocyte chemotactic protein-2, shares the highest functional homology with IL-8. Both CXCL6 and IL1A exhibit disparate regulatory effects on recruited neutrophil responses [56] [57].

### Table 2. Genes most differentially-expressed between LASV and ML29.

| GenBank accession no. | Gene symbol | Fold changes in gene expression DNA microarray |
|-----------------------|-------------|--------------------------------------------|
|                       |             | LASV  | ML29  | 4 h | 8 h | 24 h | 4 h | 8 h | 24 h |
| NM_002421             | MMP1        | –1.11 | 73.34 | 147.94 | –1.18 | –1.06 | 2.26 |
| NM_003020             | RSAD2       | 1.29  | 8.20  | 136.84 | 1.52  | 1.45  | 94.02 |
| NM_080657             | CXCL6       | –1.31 | 30.69 | 26.29  | –1.56 | 7.04  | –1.34 |
| NM_006273             | CCL7        | 1.50  | 1.69  | 30.43  | 1.94  | 1.26  | 1.60  |
| NM_002438             | MRC1        | 1.09  | 29.33 | 15.35  | –2.06 | –1.20 | –1.34 |
| AK001903              | CDNA FLJ11041 | 1.26 | 2.95  | 23.77  | –1.33 | –3.80 | –1.45 |
| NM_002346             | LY6E        | 1.26  | 2.13  | 23.77  | –1.33 | –3.80 | –1.45 |
| NM_005755             | IL1A        | 1.27  | 2.55  | 23.57  | 1.03  | 4.16  | –1.28 |
| NM_002192             | INHBA       | 1.18  | 2.48  | 20.37  | –1.55 | –3.68 | –1.07 |
| NM_006417             | IFH4        | 2.58  | 2.74  | 18.52  | 1.07  | 1.12  | 9.24  |
| NM_000361             | THBD        | 1.71  | 1.26  | 14.56  | 1.28  | 1.71  | –1.07 |
| NM_005852             | SPP1        | 1.37  | 7.94  | 14.17  | –1.24 | 1.01  | 1.14  |
| NM_000212             | ITGB3       | 1.55  | –1.29 | 12.29  | 1.79  | –1.39 | 1.48  |
| NM_013372             | GREM1       | –1.43 | 9.96  | 8.89   | –1.32 | 1.81  | –1.00 |
| NM_152594             | SPRED1      | –1.20 | 6.78  | 4.55   | –5.10 | 1.84  | 1.18  |
| NM_030776             | ZBP1        | 1.25  | 1.06  | 6.24   | 1.66  | 1.04  | 1.81  |
| NM_057749             | CCNE2       | –1.00 | 6.06  | 2.89   | –1.18 | –1.32 | –1.28 |
| NM_080546             | SLC44A1     | –1.32 | 3.33  | 1.26   | –3.23 | –1.14 | –1.26 |
| NM_033034             | TRIM5       | 1.01  | 3.77  | 4.70   | 1.03  | 1.78  | 1.77  |
| NM_194284             | CLDN23      | –1.38 | 4.58  | 3.57   | –1.35 | 1.61  | 1.10  |
| NM_000632             | ITGAM       | 1.04  | 1.16  | 4.36   | –1.12 | –1.49 | –1.55 |
| NM_018381             | Hypothetical protein FLJ11286 | 1.11 | 2.28  | 4.24   | –1.11 | 1.65  | 1.77  |
| NM_001945             | HBEGF       | 1.10  | 4.13  | 3.80   | –2.45 | –1.82 | –1.11 |
| NM_024761             | MOB1        | –1.14 | 2.53  | 4.11   | –1.83 | –1.32 | –1.07 |
| NM_000507             | FBP1        | 1.22  | 1.08  | 3.74   | –1.27 | –2.15 | –1.08 |
| NM_003739             | AKR1C3      | –1.20 | 1.41  | 3.35   | –1.37 | –1.90 | –1.24 |
| NP_005109.2           | TNFSF15     | 1.62  | 3.31  | 6.12   | 1.21  | –4.22 | –1.15 |
| NM_001946             | DUSP6       | 1.17  | 1.17  | 3.17   | 1.26  | –1.04 | –1.02 |
| NM_001423             | EMP1        | 2.56  | 1.82  | 2.99   | –3.59 | –3.12 | 1.25  |

doii:10.1371/journal.pntd.0002406.t002

Exposure and modulation of thrombomodulin expression

Due to the nature of LF disease, six LASV-upregulated genes related to the coagulation pathway were analyzed (Table 3).
Thrombomodulin (THBD), heparin-binding growth factor (HBGF), and integrin alpha M (ITGAM), were up-regulated after LASV exposure at all time-points in contrast to ML29 that down-regulated them. Plasminogen activator urokinase (PLAU) and integrin beta3 (ITGB3) were mostly up-regulated with LASV exposure and remained unchanged or down-regulated with ML29. PD-ECGF (TYMP) was slightly up-regulated after exposure to both viruses. The analysis of those coagulation-related genes using the Gene Ontology (GO) software showed interaction between them and genes related to immune response (Figure 3).

In order to validate cDNA array results, THBD expression was measured on the surface of ML29 exposed-monocytes by flow

### Table 3. Coagulation pathway genes affected by Lassa virus.

| GenBank accession no. | Name                                                                 | Gene symbol | Fold changes in gene expression DNA microarray |
|-----------------------|----------------------------------------------------------------------|-------------|-----------------------------------------------|
|                       |                                                                      | LASV        | ML29                                         |
|                       |                                                                      | 4 h  | 8 h  | 24 h | 4 h | 8 h | 24 h |
| NM_000361             | Thrombomodulin                                                      | THBD        | 1.71 | 1.26 | 14.56 | 1.28 | −1.71 | −1.07 |
| NM_001945             | Heparin-binding EGF-like growth factor                              | HBEGF       | 1.10 | 4.13 | 3.80 | −2.45 | −1.82 | −1.11 |
| NM_000632             | Integrin, alpha M (complement component 3 receptor 3 subunit)       | ITGAM       | 1.04 | 1.16 | 4.36 | −1.12 | −1.49 | −1.55 |
| NM_002658             | Plasminogen activator, urokinase                                    | PLAU        | 1.06 | 4.79 | 1.83 | −2.57 | 1.20 | 1.12 |
| NM_002121             | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)         | ITGB3       | 1.55 | −1.29 | 12.29 | 1.79 | −1.39 | 1.48 |
| NM_001953             | Endothelial cell growth factor 1 (platelet-derived)                 | PD-ECGF     | −1.10 | 2.05 | 3.30 | 1.04 | 2.43 | 1.96 |

doi:10.1371/journal.pntd.0002406.t003

![Figure 3. Gene Ontology (GO) analysis of coagulation-related genes.](image)

Gray figures represent the coagulation related genes [THBD, HBEGF, PLAU, ITGAM, ITGB3, PD-ECGF (TYMP)], affected by LASV exposure and the nodes with arrows represent key genes from the immune-response (Akt, ERK, NFκB, p38MAPK and IL1β).

doi:10.1371/journal.pntd.0002406.g003
cytometry, or quantified by ELISA in supernatants of DC exposed to LASV or ML29. There were no significant changes in thrombomodulin expression in CD14+ cells from PBMC treated with LPS or ML29 when compared with non-treated cells at 4 hpe (data not shown). However, as shown in figure 4A, there was a significant reduction in THBD expression on the surface of CD14+ cells after LPS (from ~74% control to 52% at 8 hpe and 47% at 24 hpe) or ML29 stimulus (from ~74% control to 57% at 8 hpe and 51% at 24 hpe), all in agreement with microarray results showing lower THBD RNA in ML29-exposed PBMC (Figure 1 and Table S1). DC cultures exposed to LASV secreted significantly higher levels of THBD than DC exposed to ML29 (Figure 4B), in agreement with transcriptome data. Control DC secreted 0.502 pg/ml THBD, whereas Lassa-exposed DC expressed 0.724 pg/ml THBD, significantly more than ML29-exposed DC (0.161 pg/ml). Treatment with LASV and LPS together diminished the THBD expression from 0.724 pg/ml after LASV exposure to 0.481 pg/ml.

The other coagulation-related genes could also contribute to LF disease: Plasminogen activator urokinase (PLAU) expression could be contributing to the anti-clotting effect mediated by LASV exposure. Heparin-binding epidermal growth factor-like (HB-EGF) expression is involved in several blood vessel physiologies [58], in kidney pathology [59], [60], inhibition of NF-kappa B activation [61], in cardiac hypertrophy, and together with PD-EGF promotes vascular maturation [62], [63]. The ITGB3 (CD61, platelet marker) was 12-fold up-regulated in cells exposed to LASV at 24 h. Integrins are integral cell-surface proteins composed of \( \alpha \) and \( \beta \) chains. A given chain may combine with multiple partners resulting in different integrins. The ITGB3 is found along with the \( \alpha \text{IIb} \) chain in platelets working as a receptor for fibrinogen, von Willebrand factor, plasminogen, prothrombin, thrombospondin, fibrinogen, osteopontin (SPP1), and vitronectin [64], [65], [66]. Integrins are known to participate in cell adhesion as well as cell-surface mediated signaling. High affinity LASV binding to cellular alpha-dystroglycan (\( \alpha \text{-DG} \)) receptor perturbs the signaling cross-

Figure 4. Membrane and soluble thrombomodulin (THBD) measurement. A). Cell surface THBD was detected by flow cytometry on gated CD14+ cells. This experiment was repeated with PBMC from 4 different healthy donors with similar results. After exposure to either LPS or ML29, cell-surface THBD was down-regulated by approximately 30%, at both 8 and 24 hours post exposure (hpe). According to a paired Student’s t test, this down-regulation was significant (p<0.05) at both time-points. B). Soluble THBD measured by ELISA in dendritic cell supernatants exposed to LPS inhibitor, ML29, LASS and LASS plus LPS 24 hpe. Standard deviation of THBD concentrations are shown from three different experiments. THMD from ML29 cells is significantly depressed with respect to THBD from non-exposed control cells. Lassa-exposed cells express significantly more THBD than ML29-exposed cells.

doi:10.1371/journal.pntd.0002406.g004
talk between DG and α6β1 integrins, shifting the normal signaling equilibrium towards inhibition of the MEK/ERK pathway [67]. The DG is a ubiquitous receptor for extracellular matrix (ECM) proteins, which cooperates with β1 integrins to control cell-matrix interactions.

**Discussion**

When this paper was in post-review, Malhotra et al. published results of transcriptome profiling PBMC from cynomolgous macaques infected with Lassa [68]. Their results are in good correlation with the current study and with our previous results in the LCMV-infected monkey model for LF [24] (Table S2).

As would be expected from PBMC exposure to other RNA viruses, transcriptome analysis showed that the set of IFN-stimulated genes (ISG) is the most affected after exposure to Lassa or ML29. The antiviral-ISG, including GBP1, IFI44, IFIH1, IFTI1, MX1, and LY6E, were the most common group of up-regulated genes after influenza infection [69], yellow fever vaccination [70], and during febrile episodes of dengue hemorrhagic fever [71], [72].

In comparison to the strong up-regulation by Lassa, ML29 has muted expression of INHBA (a negative regulator of IFN-γ), IFI44, TNFSF10 (TRAIL), SPP1, and LY6E (RIG-E) genes in the interferon pathway, as well as other genes related to immune response such as integrin alpha-M/beta-2 (ITGAM). These genes were down-regulated at 4, 8 and, some, 24 hpe, suggesting a mechanism to avoid recognition by the innate immune system, and to interfere with essential signals in the pathway that leads to the development of type I immunity [73], [74], [75]. For example, interferon-alpha/beta inducible IFIH44 is involved in the antiviral action of type I interferon [76], [77]. ML29 down-regulation of IFIH44 probably allows the virus to replicate early during the infection so that a strong immune response can control viral replication and spreading. In support of this notion, other antiviral genes such as RSAD2 (Viperin), and TRIM5 [78], [79], [80] were more expressed in Lassa than in ML29-exposed PBMC.

Lassa up-regulates CXCL6, an IL-8 homolog, as well as three other genes that control cell trafficking: monocyte-attracting chemokines CCL7 [81] and CCL8 (or monocyte chemotactic protein-2, MCP-2 [82] [83], and the mannose receptor C type 1 (MRC1) [84]. These in vitro responses may be related to clinical observations of higher serum IL-8 levels in patients with acute non-fatal LF than in control subjects. Levels of IL-8 and other pro-inflammatory cyto/chemokines (IL-1β, IL-6, IL-10, IP-10, TNF-α) were low or undetectable in patients with fatal LF [21] supporting our previous observations in primary human cells [18]. These observations were also confirmed in animal models of fatal LF [20], [17], [85], [30] providing no evidence for the type of “cytokine storm” observed in filovirus HF [86], [87]. The idea that an uncontrolled replication of Lassa in targets cells, DC and macrophages, is associated with a marked suppression of innate and adaptive immune responses resulting in clinical progression and death of experimental animals and LF patients is a well-accepted concept.

Bleeding is not a salient manifestation in most cases of LF. In contrast to South American arenaviral HF caused by Junin and Machupo viruses, disseminated intravascular coagulation (DIC) is rarely seen in LF patients. Nevertheless, virus-induced coagulation abnormalities and impaired vascular function is a hallmark of LF pathogenesis [3], [86]. Platelets remain either normal or moderately low, but with significantly reduced function. Plasma from LF patients has inhibitory activity on platelets from healthy individuals, suggesting the presence of soluble factors causing platelets malfunction [88]. Our previous work supports the notion that Lassa can replicate vigorously in endothelial cells without cytopathic effects but with reduced cell function, such as reduced production of interleukin IL-6 [18].

Lymphopenia and impaired lymphocyte proliferative responses are also characteristic of severe Lassa fever [99] [100]. Consequently, lymphocyte apoptosis due to Lassa up-regulation of MMP-1 and INHBA may contribute to Lassa pathogenesis.

Coagulation defects associated with LF disease could potentially be affected by Lassa up-regulation of six coagulation-related genes, the most notable being thrombomodulin (THBD). THBD is predominantly synthesized by vascular endothelial cells as a 60 kDa type I trans-membrane protein that inhibits thrombotic, inflammatory and redox related responses [90]. THBD forms a 1:1 molar complex with thrombin and significantly enhances the rate of thrombin inactivation by ATIII while accelerating activation of protein C (aPC). We observed levels of secreted THBD in dendritic cell (DC) culture medium that correlated with our transcriptome data. DC exposure to Lassa up-regulated secretion of THBD, whereas exposure to ML29 had the opposite effect. Notably, LPS treatment of Lassa-exposed cells resulted in lowering THBD as well. In the presence of thrombin, THBD generates aPC, which inhibits pro-coagulant and pro-inflammatory responses including: fibrinogen cleavage, factor V activation, platelet activation or local cytokine-induced chemotaxis for monocytes, neutrophils and up-regulation of leukocyte adhesion molecules [91], [92], [93]. It has been shown that THBD mRNA half-life is shortened by treatment of cells with IFN-γ [94]. This observation in addition to the Lassa-increased THBD expression seen here, and the absence of IFN responses seen in vitro, are in agreement with LF findings where there is no clear inflammatory response and no cellular infiltrates, in conjunction with the high viral loads seen in the presence of hemorrhagic symptoms. The absence of THBD up-regulation in the LCMV-WE infected model for LF may be a key failing of the model (see details in Table S2).

Our current hypothesis is that Lassa infects endothelial and antigen-presenting cells and increases the expression of both membrane and soluble THBD forms, activating aPC or capturing HMGB1 with anti-inflammatory and anti-coagulation effects (Figure 5). The up-regulation of THBD and its consequent anti-coagulation effects could also explain why fibrin deposits are rarely seen in histological examination of tissues from LF patients and disseminated intravascular coagulation (DIC) is rare in LF, but frequently observed in other viral hemorrhagic fevers. Given these results, inhibition of THBD could be a potential therapeutic intervention for LF.

Lassa-induced perturbation of the cross-talk between integrins and the extracellular matrix [67] may contribute to the functional alterations of epithelial and vascular endothelial cells that precede shock and death in LF patients [95]. It is also possible that, during high states of viremia, Lassa binds directly to platelets inhibiting their function. After an arterial injury, leukocytes are recruited to the site and there is an increase in ITGAM expression allowing adhesion of platelets and fibrinogen to the vessel walls [96]. We propose that Lassa induction of ITGAM could increase platelet adhesion to tissues and this may explain the decreased number of circulating platelets during hemorrhagic episodes. Platelet-derived endothelial cell growth factor (PD-ECGF) is involved in angiogenesis and wound repair [97], [98]. The differential expression of all those genes may be contributing to the non-pathogenic phenotype of ML29 and to the pathogenic phenotype of Lassa. In Lassa-infected primates, DC and macrophages were identified as prominent targets at early stages of infection, while
Kupffer cells, hepatocytes, adrenal cortical cells, and endothelial cells were more frequently infected at late stages [99]. We showed previously that mononuclear cells in PBMC are not permissive for LASV and the virus can replicate only in differentiated monocytes, DC and macrophages [18], representing less than 1% of circulating PBMC. Since LASV and ML29 replicate at the same rate in monocyte-derived cultures (ISL unpublished), the differential gene expression reported here is most likely due to differential signaling of uninfected bystander cells.

Both viruses, LASV and ML29, have identical surface-exposed GP1 responsible for interaction with α-DG; however ML29 and LASV GP2 differ by the lysine to glutamic acid (K272E) substitution located between the fusion domain and the RRLL motif, the cellular subtilase SKI1/S1P cleavage site [26] [7]. The amount of negative charge at that site in ML29 is greater than in other arenaviral GP2, and could potentially affect fusion and signaling by ML29.

In summary, exposure of human PBMC to viruses modeled the viremic stage of disease, and revealed clear differences between responses to LASV and the attenuated ML29. It remains to be shown whether the charge difference in LASV and ML29 GP2 proteins accounts for their different transcriptome profiles. ISG and genes involved in apoptotic and NF-kB pathways were among the most LASV-affected genes at 24 h after exposure. LASV and not ML29 also affected genes involved in coagulation pathways, e.g. LASV strongly up-regulates THBD suggesting a connection to the vascular abnormalities in fatal cases of LF. Based on our current knowledge about THBD involvement in pro-coagulant and pro-inflammatory pathways, THBD inhibition could be a promising drug target. Additionally, it is important to further investigate the immune response-related genes to elucidate the protective mechanisms that are undermined during LF pathogenesis.

Supporting Information

Figure S1 Cluster analysis showed that all samples clustered together by time (4, 8, and 24 hpe), by donor (3 healthy donors) and by treatment (unexposed, LASV-exposed, and ML29-exposed cells). Sample IDs are organized by Time-Donor-Stimulus-Sample number. Red color represents up-regulated genes and green color represents down-regulated genes.

Table S1 A total of 122 genes were identified as being differentially expressed at tested time-points. 136 appear in the table due to the use of more than one probe to detect the same gene. Column A shows the Affymetrix gene name. Column B
corresponds to the probe identification information. Columns C to E are the comparison between LASV exposure and un-exposed cells at different time points. Columns F to H are the comparison between ML29 and un-exposed cells at different time points. Column J has the GenBank accession number. The numbers indicate fold-changes in gene expression when compared with the control. Red color represents the more significant up-regulated genes. Green color represents the more significant down-regulated genes. 

**Table S2** SAM ANALYSIS of the RNA profiles of PBMC exposed to LASV and ML29 in vitro compared to RNA profiles of PBMC from WE/ARM infected monkeys. ~140 genes with common patterns and ~7 with different patterns, all at 24 hpc. The navy blue highlighting indicates the discrepancies in transcriptome between the LASV/ML29 pair and the LCMV-WE/ARM pair. Yellow highlighting indicates interferon pathway genes and coagulation-related genes.

**Author Contributions**
Conceived and designed the experiments: JCZ ISL MSS. Performed the experiments: JCZ SM BP RC DMW. Analyzed the data: JCZ OC YZ. Contributed reagents/materials/analysis tools: MJ JLP OC YZ. Wrote the paper: JCZ ISL MSS.
significantly enriched Gene Ontology terms associated with a list of genes.

45. Kim HK, Kim JE, Chung J, Kim YT, Kang SH, et al. (2007) Lipopolysaccharide down-regulates the thrombomodulin expression of peripheral blood monocytes: effect of serum on thrombomodulin expression in the THP-1 monocytic cell line. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 18: 157–164.

46. Tahara E, Jr., Tahara H, Kanno M, Naka K, Takeda Y, et al. (2005) G1 arrest in the Rb- and p16-dependent pathways coincides with inactivation of the phosphatidylinositol-3-kinase/Akt signaling pathway in breast cancer cell lines. Laboratory investigation; a journal of technical methods and experimental research 85: 1124–1134.

47. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, et al. (2011) FIP11 inhibits influenza A virus infection by preventing cytosolic entry. PLoS pathogens 7: e1002377.

48. Hwang IC, Bailey CC, Weyer JL, Radoshitsky SR, Becker MM, et al. (2011) Distinct patterns of FIP11-mediated restriction of flaviviruses, SARS coronaviruses, and influenza A virus. PLoS pathogens 7: e1001258.

49. Baize S, Pannezier D, Faure C, Marienneau P, Marende I, et al. (2010) Role of CD40 in macrophages and macrophage colony-stimulating factor in the development of resistance to Lassa fever in humans. Journal of immunology 184: 4607–4615.

51. Zhou S, Cerny AM, Fitzgerald KA, St Hillaire C, Anderson C, et al. (2012) Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via thrombomodulin. Cellular immunology 171: 192–197.

59. Feng L, Garcia GE, Yang Y, Xia Y, Gabbai FB, et al. (2000) Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during lipopolysaccharide administration. Journal of the American Society of Nephrology 11: 1350–1356.

69. Kash JC, Rales CF, Garcia-Sastre A, Carter V, Billiar R, et al. (2004) Global host immune response: pathogenesis and transcriptional profiling of type A influenza virus expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. Journal of virology 78: 9490–9511.

79. Quaye TD, Akosy RS, Lee EB, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology 10: 116–125.

89. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB (2000) Effective vaccine for lassa fever. Journal of virology 74: 6777–6783.

93. Cui W, Wilson JT, Wen J, Angsana J, Qu Z, et al. (2009) Thrombomodulin gene expression is associated with increased mortality in mice infected with Lassa and ML29 viruses. PLoS negated tropical diseases 4: e2171.
96. Simon DI, Dhen Z, Seifert P, Edelman ER, Ballantyne CM, et al. (2000) Decreased neointimal formation in Mac-1(−/−) mice reveals a role for inflammation in vascular repair after angioplasty. The Journal of clinical investigation 105: 293–300.

97. Hagiwara K, Steuman G, Honda H, Sahlin P, Andersson A, et al. (1991) Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene. Molecular and cellular biology 11: 2125–2132.

98. Ulger H, Karabulut AK, Pratten MK (2000) The growth promoting effects of bFGF, PD-ECGF and VEGF on cultured postimplantation rat embryos deprived of serum fractions. Journal of anatomy 197 (Pt 2): 207–219.

99. Hensley LE, Smith MA, Geisbert JB, Fritz EA, Daddario-DiCaprio KM, et al. (2011) Pathogenesis of Lassa fever in cynomolgus macaques. Virology journal 8: 205.